“The impact of tralokinumab on quality of life and school in patients aged 12–17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial” (2022) SKIN The Journal of Cutaneous Medicine, 6(6), p. s77. doi:10.25251/skin.6.supp.77.